Fin Cascade
Get Android appGet iOS app

Prices as of 8 Oct 2026 close · Not investment advice

Cohance Lifesciences Limited

NSE: COHANCEPharmaceuticals

Share price

₹442.40

-2.87% close of 8 Oct 2026

Market cap ₹16,811 CrP/E 155.7

Business score

How strong the business is, in one number. The parts behind it are in Pro.

34

out of 100 · worked out 8 Oct 2026

Your ratios

The numbers you want to see first. Tap Edit to change them.

Market cap

₹16,811 Cr

P/E ratio

155.7

P/B ratio

4.3

ROCE

5.8%

ROE

4.9%

Dividend yield

0.0%

Price & valuation chart

How the share price and its valuation have moved. Hover over the chart to see any day. Prices as of the last close.

Prices as of 8 Oct 2026 close52-week high ₹904.7552-week low ₹279.90

Answers

Simple answers to the questions investors ask most, from the company's own numbers.

How fast it has been growing

Sales fell 19.8% over the past year. Meanwhile what it keeps of every 100 rupees of sales slipped from 43.9% to 13.9% over the last four years.

Whether it grew faster than its sector

It grew 18.2% a year against a sector median of 13.1% — 5.1 percentage points faster.

Room to re-rate, or risk of de-rating

At 155.7× earnings it costs 6.5× the market, which pays 23.9× across 2199 companies we can price. Its own industry sits at 78.7×, across 5 companies. It is against its own five-year median of 59.0×, the 91st percentile of its own range.

Whether growth justifies the valuation

Its earnings are falling, so growth cannot justify the price.

Profit growthPrice per ₹1 profitPer 1% growth
Cohance Lifesciences Limited — this one-23%/yr155.7×—
Sun Pharmaceutical13%/yr33.4×₹2.6
Divi's Laboratories13%/yr83.3×₹6.4
Torrent Pharmaceuticals22%/yr78.7×₹3.6
Zydus Lifesciences32%/yr23.1×₹0.72
Laurus Labs Limited4%/yr98.6×₹24.7

Compared with companies filed under the same label. That grouping comes from the exchange's filing category, so some of them may not be real rivals.

How it compares with its peers

Against companies the exchange files under the same label (Pharmaceuticals), it ranks 99 of 130 on returns, 23 of 127 on growth, 66 of 130 on margin. That grouping comes from the exchange's filing category, so some of them may not be real rivals.

What makes it hard to beat — and is that still true?

No durable advantage shows in the numbers: it earns 5.8% on capital, ahead of 24% of companies filed under the same label. That grouping comes from the exchange's filing category, so some of them may not be real rivals.

Whether its growth pays for itself

Yes — Over the last five years it made ₹2186 crore of cash from the business, spent ₹927 crore on plant and equipment, and returned ₹904 crore to lenders and shareholders. And the profit is real: of every 100 rupees it reported over 8 years, about 117 arrived as cash (before interest, which is why it can exceed the profit). Its cash comes back more slowly than it used to: it went from being waiting 108 days for its cash to waiting 133 days for its cash.

Profit reality check

Is the profit real cash? Simple checks on the accounts. Facts only, not advice.

6 of 9 checks clear · 67%

Latest result · Q1 FY27

What the last results showed. Whether management kept its word is in Pro.

Q1 revenue fell 23% year on year, matching management's warning that the quarter would be unusually weak.

Announced 5 Aug 2026 · Consolidated · Unaudited

Revenue

₹422 Cr

Revenue vs last year

-23.1%

Revenue vs last quarter

-31.8%

Net profit

-₹45 Cr

Profit vs last year

-198.2%

Profit vs last quarter

-664.9%

Net margin

-10.7%

EPS

₹-0.63

Earnings call transcript · 5 Aug 2026

Checklist before you investPRO

Points for and against, in one list.

Key numbers & peers

The main numbers grouped by topic, and how the company compares with similar ones.

Price

Market cap
₹16,811 Cr
Prev close
₹442.40
52w High
₹918
52w Low
₹267
Enterprise value
₹17,282 Cr
Beta
0.7
Price CAGR 1y
-47.0%
Price CAGR 3y
-7.0%
Price CAGR 5y
-4.0%
Price CAGR 10y
—

Ratios

Return on assets
2.6%
PEG ratio
-6.8
P/E ratio
155.7
P/B ratio
4.3
EV / EBITDA
40.6
Industry P/E
38.0
ROCE
5.8%
ROCE 5y average
23.8%
ROE
4.9%
Debt / Equity
0.1
Interest coverage
6.6
Dividend yield
0.0%
ROE 3y average
11.0%
ROE last year
5.0%

Annual P&L

Annual revenue
₹2,269 Cr
Annual profit
₹150 Cr
Operating margin
19.0%
Net profit margin
6.6%
EBITDA margin
18.8%
Sales growth 3y
19.2%
Sales growth 5y
17.6%
Profit growth 3y
-23.0%
Profit growth 5y
-12.0%
EPS
₹4.7
Sales growth TTM
-20.0%
Profit growth TTM
-77.0%
Dividend payout
0.0%

Quarter P&L

Sales latest quarter
₹422 Cr
Profit latest quarter
-₹45 Cr
YoY quarterly sales growth
-23.1%
YoY quarterly profit growth
-197.8%
OPM latest quarter
0.3%

Balance Sheet

Book Value
₹103
Face Value
₹1.0
Total debt
₹400 Cr
Total cash
₹60 Cr
Borrowings
₹400 Cr
Reserves / Equity
101.9

Cash Flow

Operating cash flow
₹368 Cr
Free cash flow
₹169 Cr
FCF yield
0.8%
Net cash flow
-₹48 Cr

Shareholding

Promoter holding
57.5%
FII holding
6.5%
DII holding
20.1%
Public holding
15.9%

Peer comparison

CompanyPrice ₹P/EMkt cap ₹ CrDiv yield %Profit qtr ₹ CrProfit var %Sales qtr ₹ CrSales var %ROCE %
Sun Pharma.Inds.1,781.0033.84,27,3220.902,901.26.015,299.910.520.5
Divi's Lab.9,588.0085.42,54,5310.31902.065.53,080.027.822.0
Torrent Pharma.4,716.2080.41,79,3890.81566.05.84,921.054.915.2
Zydus Lifesci.1,153.0023.61,15,0120.09990.2-35.18,017.022.021.1
Laurus Labs2,052.80101.41,10,9150.10362.1125.52,026.329.117.8
Cipla1,327.2030.01,07,2210.98785.6-39.27,119.32.315.5
Mankind Pharma2,500.0048.41,03,2610.04574.129.64,030.612.913.5
Cohance Life455.45161.817,4250.00-45.2-144.2422.3-23.15.8
Median417.9034.52,2080.0713.529.5164.018.415.0

Competes with: Aurobindo Pharma, Cipla, Divi's Laboratories, Dr Reddy's Laboratories, Laurus Labs Limited, Lupin, Mankind Pharma Limited, Sun Pharmaceutical, Symbiotec Pharmalab Limited, Torrent Pharmaceuticals, Zydus Lifesciences

Quarterly results

Sales and profit for each of the last 13 quarters. Newest on the right. ₹ crore.

Consolidated · to 30 Jun 2026
Line itemJun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales348231220253488604676840549556545619422
Expenses181133154180363398439611437435449520421
Material Cost178192197139159
Change in Inventories-30-50-3875-38
Purchases of Stock-in-Trade00000
Employee Cost133127119129133
Other Expenses156167172177168
Operating Profit16798667312520523722911212195991
OPM %4842302926343527202218160.27
Other Income11201417191622-46161-1812
Exceptional items (within Other Income)-8.100-4.86-170
Interest102210101110109997
Depreciation13121317313844544544475150
Profit before tax164105657110317420516163844120-43
Tax %2625292527212527262129585
Net Profit121804753751381531174666298-45
EPS in Rs4.743.131.842.102.965.446.014.731.281.940.960.51-0.63
Diluted EPS in Rs1.271.930.960.50-0.65

Profit & loss

Yearly sales, costs and profit for 12 years, plus the last 12 months (TTM). ₹ crore.

Consolidated · to 31 Mar 2026
Line itemMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales3788341,0101,3201,3401,0512,6092,2692,142
Expenses2064495677387666451,8111,8411,825
Material Cost705
Change in Inventories-43
Purchases of Stock-in-Trade0
Employee Cost508
Other Expenses671
Operating Profit172385443582574406797427316
OPM %454644444339311915
Other Income16668133466253411
Exceptional items (within Other Income)-29
Interest323129137413734
Depreciation122432394855167187192
Profit before tax158405468668560406643207101
Tax %3122233227262527
Net Profit10931736245441130048415059
EPS in Rs1214181612194.682.78
Diluted EPS in Rs4.68
Dividend Payout %-020142837-0-0-0

Compounded growth

Average yearly growth over different spans, as stored. A span can cross a demerger or an acquisition.

Compounded sales growth

10 years
—
5 years
18%
3 years
19%
TTM
-20%

Compounded profit growth

10 years
—
5 years
-12%
3 years
-23%
TTM
-77%

Stock price CAGR

10 years
—
5 years
-4%
3 years
-7%
1 year
-47%

Return on equity

10 years
—
5 years
15%
3 years
11%
Last year
5%

Balance sheet

What the company owns and what it owes, at the end of each year. ₹ crore.

Consolidated
Line itemMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital-013252525252538
Reserves5788321,1551,5021,7102,0253,6233,873
Borrowings83186143977065486400
Other Liabilities1231421512051601381,3461,415
Minority Interest123
Total Liabilities7831,1731,4741,8301,9662,2545,4805,727
Fixed Assets2713574415346636703,1073,369
CWIP1111029630165179334178
Investments7338542598536904337529
Other Assets3943763956676015011,7021,652
Total Assets7831,1731,4741,8301,9662,2545,4815,727

Cash flows

Real money coming in and going out each year — from the business, from investments and from loans. ₹ crore.

Consolidated
Line itemMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity50407383330457358673368
Cash from Investing Activity-65-413-311-136-195-362-388-251
Cash from Financing Activity267-76-156-242-14-327-165
Net Cash Flow111-53720-18-42-48
Free Cash Flow-6304272255171307357169

Ratios

How fast customers pay, how long stock sits, and how well capital earns — year by year.

Consolidated
Line itemMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days1425137653046108110
Inventory Days556278243259279268209310
Days Payable190113100976349120157
Cash Conversion Cycle509217180228247265197263
Working Capital Days205645610899115106133
ROCE %5040413219216

Shareholding pattern

Who owns the company — founders (promoters), foreign funds, Indian funds and the public. In %.

Consolidated · to 30 Jun 2026
Line itemSep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Promoters606050505050506657575757
FIIs10109.549.801111117.236.516.015.596.50
DIIs141617171717171121222220
Government0.010.010.010.010.010.010.010.010.010.010.010.01
Public161423232222221515151516
No. of Shareholders73,71570,05268,93265,77769,33784,21086,32580,91075,28481,87785,23099,149

Price trend

The price as a Renko brick chart: small moves drop out so the bigger path stands out.

Change over 1 year -49.8% (₹881.50 → ₹442.40)Brick size ₹17.53 (fixed)Bricks 54
₹400₹600₹800₹442Nov '25Feb '26May '26Aug '26
Price moved up one brickPrice moved down one brickLast close ₹442.40 on 8 Oct 2026

Every brick is the same size, about one typical day's move. A new brick needs a full brick's move; turning the other way needs two. Bricks show where the price went, not where it will go.

Open interestPRO

Where option traders are positioned on this stock.

Industry numbers

The numbers that matter most in this industry, from the company's own filings.

1 when an audit qualification is filed as repetitive

0.00flag

2026-03-31

the company's own unlisted debt securities in default at period end

0.00cr

2026-06-30

the company's own loans / revolving facilities in default at period end (standalone filing)

0.00cr

2026-06-30

guarantees / comfort given for promoter, promoter group, directors and KMP

0.00cr

2026-03-31

loans outstanding to promoter, promoter group, directors and KMP (governance filing)

0.00cr

2026-03-31

security given for the borrowing of promoter, promoter group, directors and KMP

0.00cr

2026-03-31

FY revenue / permanent employees + workers, same basis (calc)

72,23,408inr

2026-03-31

News

News and filings about Cohance Lifesciences Limited. Open one to see why it matters.

No recent news for this company.

Supply chain

Who it buys from, sells to and competes with — as recorded in our map of company links.

Competes with

Uses as raw material

  • cyanide reagents / cyanidation inputs
  • hydrogenation / Grignard / halogenation / cryogenic-chemistry inputs
  • key starting materials (KSMs) and advanced intermediates
  • packing materials
  • raw materials for pharmaceutical APIs/intermediates

Depends on the price of

  • fuel

Buys from

About

What the company is, from our own records: where it sits, where it makes things, and what it is made of.

Sector
Healthcare
Industry
Pharmaceuticals
Classification
Healthcare › Pharmaceuticals
ISIN
INE03QK01018

Plants

  • API R&D Unit-I / Genome Valley R&D Center · Hyderabad / Shamirpet, Telangana
  • API R&D Unit-II / Ankleshwar · Ankleshwar, Gujarat
  • API Unit-I / Jaggayapet Manufacturing Site · Jaggayapet, Andhra Pradesh
  • API Unit-II / Atchutapuram · Atchutapuram, Andhra Pradesh
  • API Unit-III / Ankleshwar Manufacturing Site · Ankleshwar, Gujarat
  • API Unit-IV / Nacharam Manufacturing Site · Hyderabad, Telangana
  • API Unit-V / Parawada Manufacturing Site · Parawada / Visakhapatnam, Andhra Pradesh
  • FDF Unit-I / Nacharam · Hyderabad, Telangana
  • FDF Unit-II / Jadcherla · Jadcherla, Telangana
  • FDF Unit-III / Pashamylaram · Pashamylaram, Telangana
  • FDF Unit-IV / Shamshabad · Shamshabad, Telangana
  • NJ Bio cGMP bioconjugation facility · Princeton, New Jersey, USA

News impact

Big market events that reach Cohance Lifesciences Limited, and how the effect spreads.

Who it hits first

  • Fortis Healthcare, the hospital chain, faces a court-ordered forensic audit, meaning outside accountants will dig through its books while investors price in governance risk.
  • InGovern, the governance adviser, warns the order could let lenders chase listed companies for their promoters' (founding owners') personal debts, blurring the line between a company and its owners.
  • Hospital shares with heavy promoter pledging (founders' shares posted as loan collateral), like Aster DM at 40.66% pledged and Cohance at 94.56% pledged, face the sharpest sentiment hit.
  • Stronger hospital operators such as Apollo and Max, with solid returns and low pledges, face only a mild sector-wide discount rather than a direct hit.

Who may gain

  • Rival hospital chains like Apollo Hospitals and Max Healthcare could pick up a few patients if Fortis managers are distracted by the audit, though the pack shows no booking shift yet.
  • Governance advisers and law firms that run forensic audits and promoter-debt opinions may win fresh mandates from cautious boards.
  • Low-pledge, high-return drug makers may look relatively safer as cautious investors rotate away from pledged names.

Along the supply chain

Downstream

Fortis sells care directly to patients rather than to companies (the pack lists no downstream customers), so there is no buyer order chain to disrupt — the hit lands on patient confidence and the share price, not on a customer.

Upstream

NephroPlus, the dialysis operator named as a Fortis supplier, plus Interarch, the building-products supplier, face no direct order cut since a book audit cancels no dialysis sessions or hospital buildings, though a long probe could slow Fortis expansion orders.

Where demand moves

Business

Hospital visits and planned surgeries at Fortis could soften if patients and referring doctors turn cautious during the audit, with a small spillover of footfall to nearby Apollo, Max and Aster hospitals; drug and lab-equipment orders show no direct change since the order targets books, not prescriptions.

Capital

Investors are likely to trim Fortis and high-pledge healthcare names and rotate toward low-pledge, high-return peers or cash, widening the gap between PE 63.48 Fortis and names nearer sector median 44.03.

How it spreads across sectors

Financial Services

Lenders and NBFCs (shadow banks) watch whether courts let them reach listed-company assets for promoter loans, which could reshape collateral terms over months.

Healthcare

Hospital stocks trade with a wider governance discount, sharpest for high-pledge names, while drug makers with no hospital link barely move.

When it plays out

Immediate

Fortis shares wobble on audit headlines and governance commentary while high-pledge peers slip in sympathy.

Medium term

Audit findings decide the path — a clean report unwinds the discount, while adverse findings or an upheld precedent invite fresh risk talk.

Short term

Lawyers parse the court order's scope; any clarification limiting the precedent calms peers, while talk of wider enforcement keeps pledged names soft.

Who it hits first

  • Launch-heavy drug makers (Sun, Cipla) gain months of extra sales per approval.
  • API suppliers and CDMOs see more client molecules to make.
  • Hospitals unaffected — approvals do not fill beds.

Who may gain

  • Sun Pharma most in absolute terms; quality API makers (Gujarat Themis) on volumes.

Along the supply chain

Downstream

Distributors and pharmacies stock more new products; hospitals mostly unaffected.

Upstream

API and intermediate makers gain volumes as more launches need ingredients.

Where demand moves

Business

Approval queues shorten; API/CDMO order books lengthen; patients access drugs sooner.

Capital

Money rotates into launch-heavy pharma and quality API names; avoids weak-balance-sheet theme traps.

How it spreads across sectors

Healthcare

Pharma and CDMO positive with a lag; hospitals neutral; weak names are value traps.

When it plays out

Immediate

Pharma stocks firm 1-3% on sentiment; weak names jump most (sell the jump).

Medium term

Actual approval acceleration over 1-3 years compounds launch-heavy winners.

Short term

Draft details and implementation dates decide how much is real vs hope.

Who it hits first

  • Piramal Pharma faces CDMO order pauses, deeper client audits and remediation costs at Morpeth.
  • Seven observations exceed its own 4-observation precedents, signaling a tougher inspection outcome.
  • Small pharma peers derate on sentiment as investors re-check Indian plant quality systems.

Who may gain

  • Large quality leaders (Sun, Divi) may pick up marginal CDMO inquiries — too small to trade.

Along the supply chain

Downstream

US clients of Morpeth qualify backup suppliers slowly; no drug shortages indicated.

Upstream

No direct supply-chain link — this is a plant-quality event, not a supply disruption; API suppliers to Morpeth see minor order delays.

Where demand moves

Business

CDMO clients slow new Piramal orders and audit harder; no demand transfers at scale to peers.

Capital

Money trims small-pharma exposure on regulatory headlines; rotates to large quality pharma and hospitals-on-facts.

How it spreads across sectors

Healthcare

CDMO/API sentiment hit; hospitals untouched operationally; large pharma flat per precedent.

When it plays out

Immediate

Piramal stock down 2-5% on the headline; small peers dip 1-3% on sentiment.

Medium term

Clean re-inspection closes the episode; warning letter or import alert would extend damage to quarters.

Short term

Company corrective-action response and FDA classification (VAI vs OAI) decide whether this fades or escalates.

Who it hits first

  • Granules faces 2-4% technical pressure from Rs 1,500 cr of new free float
  • Quality buyers (Goldman, BNP) validate the business and likely mark a near-term floor
  • Pharma peers see no fundamental change — ranked names are sentiment-only

Who may gain

  • Goldman Sachs, BNP Paribas and other block buyers who accumulated at a discount
  • Granules' public float and liquidity improve post-deal

Along the supply chain

Downstream

Formulation customers and distributors are unaffected; pricing and contracts continue as before.

Upstream

No supply-chain link — API suppliers and job-workers see no order change from a share sale.

Where demand moves

Business

No business demand shifts — this is a pure ownership transfer; Granules' API and formulations orders are untouched.

Capital

Promoter supply meets institutional demand at a small discount; some weak holders exit on the news while quality funds accumulate — net neutral to mildly positive for the register.

How it spreads across sectors

Healthcare

neutral — single-stock block with quality buyers; no sector read-through

When it plays out

Immediate

Granules dips 2-4% on supply overhang; peers flat

Medium term

Non-event for earnings — price rejoins fundamentals within a quarter

Short term

Block gets absorbed in 1-2 weeks; quality-holder register supports stability

Dividends, splits & big trades

Money paid out, share splits and buybacks, and big buys or sells by funds and insiders.

Dividends

9 Sep 2022special₹5
9 Sep 2022interim₹1
13 May 2022special₹1
13 May 2022interim₹1
15 Feb 2022special₹2
15 Feb 2022interim₹1
13 Aug 2021unspecified₹1
17 Feb 2021interim₹1

Splits, bonuses & buybacks

  • daily-prices repair: 1 rows from NSE's archive (replace 0, delete 0, insert 1), 2026-02-01..2026-02-01 (docs/flat_day_repair.md)1× · 1 Feb 2026
  • nse-rename-history fill: 1280 NSE bars before cutoff, ISIN INE03QK01018@2020-03-09, symbols SUVENPHAR (docs/nse_rename_history.md)1× · 8 May 2025
  • nse-rename-history step: Bonus 1:1 (NSE corporate action, ex 2020-09-25)0.5× · 25 Sep 2020

Documents

Annual reports, results presentations and earnings calls, straight from the source.

Facts from company filings and exchange data. Not investment advice: nothing here tells you to buy or sell.